Tepezza (teprotumumab-trbw) is a medication used for the treatment of thyroid-associated ophthalmopathy (TAO), a rare autoimmune disease that affects the eyes. While Tepezza has shown to be effective in managing TAO symptoms, it is important to be aware of potential side effects.
One side effect reported after taking Tepezza is temporary or permanent hearing loss. Another side effect that has been reported is tinnitus, which is the perception of sound in the ears without any external source. Tinnitus is a condition that can manifest as ringing, buzzing, hissing, or other noises in the ears. It can be intermittent or constant and may vary in intensity. While the exact mechanism of how Tepezza may cause hearing loss or tinnitus is not fully understood, it is believed to be related to the medication’s impact on the immune system and possible inflammation that can occur as a result. Recently, a study published in the medical journal Endocrine Practice showed that 16% (20) of 121 patients reported adverse events related to hearing from Tepezza. Twelve of the 20 reported tinnitus, hearing loss/impairment, hyper/hypoacusis, autophony, or eustachian tube dysfunction. If you took Tepezza and suffered from permanent deafness, tinnitus, or hearing loss, you may be eligible for compensation.
Who qualifies for potential compensation?
If you took Tepezza and were harmed by hearing loss and/or tinnitus, you may be eligible for compensation. Justpoint works to investigate potentially harmful medications like Tepezza in order to recover compensation for those that were affected while preventing future damage. We work with some of the top-rated attorneys in the US, and always put our clients’ needs first. If you or a loved one were harmed by Tepezza, schedule a free consultation today.
References
US Food and Drug Administration. Tepezza Prescribing information. Accessed July 24, 2023: https://www.hzndocs.com/TEPEZZA-Prescribing-Information.pdf
Terry J. Smith, MD, Qianhong Fu, MS, Robert J. Holt, PharmD, MBA. Hearing-Related Adverse Events and Quality of Life Assessments in Thyroid Eye Disease Patients Treated with Teprotumumab. Endocrine Practice. DOI: https://doi.org/10.1016/j.eprac.2023.03.245
